ISRG
Wall Street’s mood swing
Intuitive Surgical is getting the classic Wall Street treatment: lots of praise, less enthusiasm for the price tag. In the latest analyst chatter, Truist trimmed its price target to $580, UBS cut to $550, and other firms nudged their numbers around like they were rearranging chairs on a moving ship.
Still a fan club — just a cautious one
The consensus rating is still sitting around Moderate Buy, and a few firms are even sounding extra cheerful. TD Cowen bumped ISRG to a strong-buy call, Piper Sandler kept an overweight rating, and Sanford Bernstein actually raised its target to $750. So no, the robot-surgery party is not over.
But the vibe has clearly shifted from "how high can this go?" to "let’s not get carried away." When a stock is trading around $458 and analysts are slicing targets in both directions, you’re looking at a market that still likes the business but is getting picky about the valuation.
Why investors should care
This isn’t just analyst noise in a vacuum. The article also flags safety and cybersecurity headlines tied to stapler/reload products and an administrative-network breach, plus about $17.28 million in insider selling over the last three months. That’s the kind of cocktail that can make investors squint a little harder before Q1 results.
Big picture: Intuitive Surgical still has plenty of believers, but the stock may need a fresh catalyst — not just more love letters from Wall Street — to get its groove back.